Tailored drug therapy for mitigating drug-induced liver injury: Is this the era of genetic screening?

Personalized Medicine

Volumn 7, Issue 1, 2010, Pages 5-8

  Huang, Yi Shin ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ATAZANAVIR; AZATHIOPRINE; BIOLOGICAL MARKER; CARBAMAZEPINE; DICLOFENAC; DIVERSE; DRUG; FLUCLOXACILLIN; INDINAVIR; ISONIAZID; METHOTREXATE; PERHEXILINE; TACRINE; TICLOPIDINE; TOLCAPONE; TROGLITAZONE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; XIMELAGATRAN;

ADVERSE DRUG REACTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHROMOSOME; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; EPIGENETICS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOMICS; GENOTYPE; HUMAN; INCIDENCE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION; LIVER INJURY; LIVER TOXICITY; OUTCOME ASSESSMENT; OXIDATION; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TOXIC HEPATITIS; TREATMENT WITHDRAWAL; UNITED STATES;

EID: 74049110409     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.09.69     Document Type: Editorial

References (32)

1. Yi-Shin Huang 1 Daly AK, Donaldson PT, Bhatnagar P et al.: HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41(7), 816-819 (2009). ■■ Successful model of a genome-wide study to detect the biomarkers of drug-induced liver injury.
2. Huang YS, Chern HD, Su WJ et al.: Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor of antituberculosis drug-induced hepatitis. Hepatology 35(4), 883-889 (2002). ■ Frequently cited paper to demonstrate slow acetylators as a risk factor of anti-tuberculosis hepatitis, using the NAT2 genotyping.
3. Huang YS, Chern HD, Su WJ et al.: Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37(4), 924-930 (2003).
4. Huang YS, Su WJ, Huang YH et al.: Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H: quinone oxidoreductase, glutathione S-transferase M1 and T1 and the susceptibility to drug-induced liver injury. J. Hepatol. 47(1), 128-134 (2007).
5. Ohno M, Yamaguchi I, Yamamoto I et al.: Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int. J. Tuberc. Lung Dis. 4(3), 257-261 (2000).
6. Roy B, Chowdhury A, Kundu S et al.: Increased risk of antituberculosis druginduced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J. Gastroenterol. Hepatol. 16(9), 1033-1037 (2001).
7. Roy B, Ghosh SK, Sutradhar D et al.: Predisposition of antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatric patients. J. Gastroenterol. Hepatol. 21(4), 784-786 (2006).
8. Vuilleumier N, Rossier MF, Chiappe A et al.: CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur. J. Clin. Pharmacol. 62(6), 423-429 (2006).
9. Cho HJ, Koh WJ, Ryu YJ et al.: Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis 87(6), 551-556 (2007).
10. Leiro V, Fernandez-Villar A, Valverde D et al.: Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int. 28(6), 835-839 (2008).
11. Kim SH, Kim SH, Bahn JW et al.: Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 10(11), 1767-1779 (2009).
12. Tomalik-Scharte D, Lazar A, Fuhr U, Kirchheiner J: The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J. 8(1), 4-15 (2008).
13. Barclay ML, Sawyers SM, Begg EJ et al.: Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics 13 (10), 627-632 (2003).
14. Ueda K, Ishitsu T, Seo T et al.: Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity. Pharmacogenomics 8(5), 435-442 (2007).
15. Simon T, Becquemont L, Mary-Krause M et al.: Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin. Pharmacol. Ther. 67(4), 432-437 (2000).
16. Watanabe I, Tomita A, Shimizu M et al.: A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with Type 2 diabetes mellitus. Clin. Pharmacol. Ther. 73(5), 435-455 (2003).
17. Lucena MI, Andrade RJ, Martínez C et al.: Glutathione-S-transferase M1 and T1 null genotypes as susceptibility factor for idiosyncratic drug-induced liver injury. Hepatology 48(2), 588-596 (2008).
18. Imanishi H, Okamura N, Yagi M et al.: Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J. Hum. Genet. 52(2), 166-171 (2007).
19. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP: Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132(1), 272-281 (2007).
20. Acuna G, Foernzler D, Leong D et al.: Pharmacogenetic ana lysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J. 2(5), 327-334 (2002).
21. Boyd MA, Srasuebkul P, Ruxrungtham K et al.: Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenet. Genomics 16(5), 321-329 (2006).
22. Lankisch TO, Behrens G, Ehmer U et al.: Gilbert's syndrome and hyperbilirubinemia protease inhibitor therapy: an extended haplotype of genetic variants increases risk in indinavir treatment. J. Hepatol. 50(5), 1010-1018 (2009).
23. Lankisch TO, Moebius U, Wehmeier M et al.: Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 44(5), 1324-1332 (2006).
24. Heckmann JM, Lambson EM, Little F, Owen EP: Thiopurine methyltransferase (TPMT) heterozygosity and enzyme activity as predictive tests for the development of azathioprine-related adverse events. J. Neurol. Sci. 231(1-2), 71-80 (2005).
25. Hautekeete ML, Horsmans Y, Van Waeyenberge C et al.: HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 117(5), 1181-1186 (1999).
26. O'Donohue J, Oien KA, Donaldson P et al.: Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 47, 717-720 (2000).
27. Hirata K, Takagi H, Yamamoto M et al.: Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 8(1), 29-33 (2008).
28. Kindmark A, Jawaid A, Harbron CG et al.: Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8(3), 186-195 (2008).
29. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK: Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am. J. Respir. Crit. Care Med. 166(7), 916-919 (2002).
30. Andrade RJ, Lucena MI, Alonso A et al.: HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 39(6), 1603-1612 (2004).
31. Aithal GP, Ramsay L, Daly AK et al.: Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39(5), 1430-1440 (2004).
32. Carr DF, Alfirevic A, Tugwood JD et al.: Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity. Pharmacogenet. Genomics 17(11), 961-972 (2007).